1990—2019年中国非酒精性脂肪性肝炎相关肝癌疾病负担分析

doi:10.12183/j.scjpm.2024.0792

摘要/Abstract

摘要： 目的全面评估1990—2019年中国非酒精性脂肪性肝炎相关肝癌（Non-alcoholic steatohepatitis associated hepatocellular carcinoma,NASH-HCC）的疾病负担状况及流行趋势。方法利用2019年全球疾病负担数据库,结合Joinpoint回归模型,探究1990—2019年年龄、性别、时期、吸烟、过高空腹血糖等因素对中国NASH-HCC疾病负担的影响,并比较同时期中、美、全球负担差异。结果中国NASH-HCC标化患病率1990—1996年上升1.55%,1996—2001年下降3.89%,2001—2005年下降16.25%,2010—2019年上升3.39%,与同期我国非酒精性脂肪性肝病疾病负担变化趋势一致,男性疾病负担高于女性,老年患者更多见,2次上升分别提示医疗水平、饮食结构、生活方式等因素在NASH-HCC负担变化中的重要意义;抽烟和高空腹血糖对65~69岁男性疾病负担影响最大;美国疾病负担不断上升、患病率超过中国,但中国NASH-HCC疾病负担整体仍处于全球高位。结论 NASH-HCC疾病负担是中国一项重大的公共卫生挑战,需重点关注。

关键词: 非酒精性脂肪性肝炎相关肝癌, 疾病负担, 数据分析

Abstract: Objective To comprehensively evaluate the disease burden and prevalence trend of non-alcoholic steatohepatitis associated hepatocellular carcinoma (NASH-HCC) in China from 1990 to 2019. Methods Using the Database of Global Burden of Disease Study 2019 and Joinpoint regression model, we explored the influences of factors such as age, gender, period, smoking, and high fasting plasma glucose on the disease burden of NASH-HCC in China from 1990 to 2019. What's more, the differences of disease burden were compared between China, the United States, and the world at the same period. Results The standardized prevalence rate of NASH-HCC in China increased by 1.55% from 1990 to 1996, decreased by 3.89% from 1996 to 2001, decreased by 16.25% from 2001 to 2005, and increased by 3.39% from 2010 to 2019. With the same changing trend of non-alcoholic fatty liver disease burden in China during the same period. Meanwhile, it was with a higher disease burden in males and older people. The two increases indicated the importance of factors including of medical level, diet structure, and lifestyle in the change of NASH-HCC burden. Smoking and high fasting plasma glucose had the greatest impacts on disease burden in males aged 65-69 years. Although the burden of disease in the United States was rising, and with a higher prevalence rate than in China, there was a higher level of overall burden of NASH-HCC in China than the global. Conclusions The disease burden of NASH-HCC is a major public health challenge in China. The government and individuals should pay more attention.

Key words: Non-alcoholic steatohepatitis associated hepatocellular carcinoma, Disease burden, Data analysis

中图分类号:

R195

章妍, 曲英迪, 姚君怡, 王允亮. 1990—2019年中国非酒精性脂肪性肝炎相关肝癌疾病负担分析[J]. 华南预防医学, 2024, 50(9): 792-799.

ZHANG Yan, QU Yingdi, YAO Junyi, WANG Yunliang. Disease burden related to non-alcoholic steatohepatitis associated hepatocellular carcinoma in China, 1990 - 2019[J]. South China Journal of Preventive Medicine, 2024, 50(9): 792-799.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Jiang D, Zhang L, Liu W, et al.Trends in cancer mortality in China from 2004 to 2018: A nationwide longitudinal study[J]. Cancer Commun (Lond), 2021, 41(10): 1024-1036.
[3] Estes C, Anstee QM, Arias-Loste MT, et al.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J].J Hepatol, 2018, 69(4): 896-904.
[4] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019BD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J].Lancet, 2020, 396(10258): 1223-1249.
[5] 李辉章,杜灵彬. Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用[J].中华预防医学杂志,2020,54(8):908-912.
[6] Chen HS, Zeichner S, Anderson RN, et al.The joinpoint-jump and joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics[J]. J Off Stat, 2020, 36(1): 49-62.
[7] Pang J, Chen K, Chen S, et al.Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990-2019: A systematic analysis for the GBD 2019[J]. Diabetol Metab Syndr, 2022, 14(1): 112.
[8] 蔡仕良. 肝癌中调控雄激素受体致癌通路的关键分子研究[D].上海:中国人民解放军海军军医大学,2022.
[9] 王瑞华,蔡仕良,柳东红,等. 雄激素/雄激素受体信号通路在肝细胞癌中的研究进展[J].肿瘤防治研究,2023,50(2):180-185.
[10] Ko SH, Jung Y.Energy metabolism changes and dysregulated lipid metabolism in postmenopausal women[J]. Nutrients, 2021, 13(12): 4556.
[11] 代志新,杜鹏,董隽含.中国老年抚养比再估计与人口老龄化趋势再审视[J].人口研究,2023,47(3):94-107.
[12] 肖文博,朱广涵,朱云,等. 1990—2019年中国主要消化系统恶性肿瘤发病变化分析[J].中国肿瘤,2022,31(9):693-700.
[13] 苏昌太. 新时代中国特色医疗保障体系的内涵意蕴、演化历程和实践进路[J].商业经济,2023(6):149-151.
[14] 刘嵘,程永德,王小林,等. 中国肝细胞癌TACE治疗的历史、现状和展望—纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(8):743-746.
[15] 叶晨,黄晓婕,苏米亚·艾合买提江,等. 中国居民膳食炎症指数情况及变化趋势[J].中国食物与营养,2023,29(2):85-89.
[16] Doukas SG, Vageli DP, Doukas PG, et al.The effect of tobacco smoke N-Nitrosamines, NNK and NDEA, and nicotine, on DNA mismatch repair mechanism and miRNA markers, in hypopharyngeal squamous cell carcinoma: An in vivo model and clinical evidence[J]. Curr Oncol, 2022, 29(8): 5531-5549.
[17] 王敬鑫,赵健,石钰霖,等. 主动吸烟所致中国人群消化系统恶性肿瘤风险的meta分析[J].中华肿瘤防治杂志,2023,30(9):546-556.
[18] Zou Z, Wang H, d'Oleire Uquillas F, et al. Definition of substance and non-substance addiction[J].Adv Exp Med Biol, 2017, 1010: 21-41.
[19] 中华医学会内分泌学分会,中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识[J]. 中华内分泌代谢杂志,2021,37(7):589-598.
[20] Soeda K, Sasako T, Enooku K, et al.Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis[J]. Nat Commun, 2023, 14(1): 6584.
[21] Yang JD, Ahmed F, Mara KC, et al.Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J].Hepatology, 2020, 71(3):907-916.
[22] 谭洋阳,曹霞. 跨文化视角下饮食文化的差异研究—以中美两国为例[J].现代食品,2021,(8):38-39,50.
[23] Younossi ZM, Blissett D, Blissett R, et al.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J]. Hepatology, 2016, 64(5): 1577-1586.